FAP and neoplasm: The development of the selective and potent FAP inhibitor UAMC-1110 has led to synthetization of other promising radiolabelled FAP inhibitors tested in different tumour entities (FAPIs) [98,99,100,101,102,103,104,105,106,107,108,109,110].